NeuroAct Communication offers independent consulting in neuropharmacology and preclinical drug discovery to
bioscience companies, agencies and the investment community.
offers professional and independent advice
at each stage of early CNS drug discovery.
Read the latest news from NeuroAct Communication
was founded by Adrian Newman-Tancredi PhD DSc
an experienced industrial neuropharmacologist.
Expertise in CNS Drug Discovery
Preclinical pharmacology of antipsychotics,
antidepressants, anti-Parkinsonian drugs and analgesics.